APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Heterozygous Familial Hypercholesterolemia Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Heterozygous Familial Hypercholesterolemia Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 173998390319 December 2025174 pages

Choose your research edition.

Industry ResearchHeterozygous Familial Hypercholesterolemia Drug Industry Research Report 2026106 pages · $2,950 USDIndustry Growth & TrendsGlobal Heterozygous Familial Hypercholesterolemia Drug Industry Growth and Trends Forecast to 203270 pages · $3,450 USDMarket StructureGlobal Heterozygous Familial Hypercholesterolemia Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032174 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Heterozygous Familial Hypercholesterolemia Drug Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Heterozygous Familial Hypercholesterolemia Drug Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Heterozygous Familial Hypercholesterolemia Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Heterozygous Familial Hypercholesterolemia Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Heterozygous Familial Hypercholesterolemia Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Heterozygous Familial Hypercholesterolemia Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Heterozygous Familial Hypercholesterolemia Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Heterozygous Familial Hypercholesterolemia Drug include Madrigal Pharmaceuticals Inc, Gemphire Therapeutics Inc, Esperion Therapeutics Inc and Daewoong Co Ltd, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Heterozygous Familial Hypercholesterolemia Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Heterozygous Familial Hypercholesterolemia Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Heterozygous Familial Hypercholesterolemia Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Heterozygous Familial Hypercholesterolemia Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Heterozygous Familial Hypercholesterolemia Drug Segment by Company

Madrigal Pharmaceuticals Inc

Gemphire Therapeutics Inc

Esperion Therapeutics Inc

Daewoong Co Ltd

Heterozygous Familial Hypercholesterolemia Drug Segment by Type

Gemcabene Calcium

ST-103

MGL-3196

Others

Heterozygous Familial Hypercholesterolemia Drug Segment by Application

Clinic

Hospital

Others

Heterozygous Familial Hypercholesterolemia Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Heterozygous Familial Hypercholesterolemia Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Heterozygous Familial Hypercholesterolemia Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Heterozygous Familial Hypercholesterolemia Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Heterozygous Familial Hypercholesterolemia Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Heterozygous Familial Hypercholesterolemia Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Heterozygous Familial Hypercholesterolemia Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Heterozygous Familial Hypercholesterolemia Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Heterozygous Familial Hypercholesterolemia Drug Industry Trends Table 2. Heterozygous Familial Hypercholesterolemia Drug Industry Drivers Table 3. Heterozygous Familial Hypercholesterolemia Drug Industry Opportunities and Challenges Table 4. Heterozygous Familial Hypercholesterolemia Drug Industry Restraints Table 5. Global Heterozygous Familial Hypercholesterolemia Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Heterozygous Familial Hypercholesterolemia Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Heterozygous Familial Hypercholesterolemia Drug Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Manufacturers Table 9. Global Heterozygous Familial Hypercholesterolemia Drug Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Heterozygous Familial Hypercholesterolemia Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Heterozygous Familial Hypercholesterolemia Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Heterozygous Familial Hypercholesterolemia Drug Manufacturers, Product Type & Application Table 13. Global Heterozygous Familial Hypercholesterolemia Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Heterozygous Familial Hypercholesterolemia Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Gemcabene Calcium Table 17. Major Manufacturers of ST-103 Table 18. Major Manufacturers of MGL-3196 Table 19. Major Manufacturers of Others Table 20. Global Heterozygous Familial Hypercholesterolemia Drug Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Heterozygous Familial Hypercholesterolemia Drug Sales by Type (2021-2026) & (K Units) Table 22. Global Heterozygous Familial Hypercholesterolemia Drug Sales by Type (2027-2032) & (K Units) Table 23. Global Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Type (2021-2026) Table 24. Global Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Type (2027-2032) Table 25. Global Heterozygous Familial Hypercholesterolemia Drug Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 26. Global Heterozygous Familial Hypercholesterolemia Drug Revenue by Type (2021-2026) & (K Units) Table 27. Global Heterozygous Familial Hypercholesterolemia Drug Revenue by Type (2027-2032) & (K Units) Table 28. Global Heterozygous Familial Hypercholesterolemia Drug Revenue Market Share by Type (2021-2026) Table 29. Global Heterozygous Familial Hypercholesterolemia Drug Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Clinic Table 31. Major Manufacturers of Hospital Table 32. Major Manufacturers of Others Table 33. Global Heterozygous Familial Hypercholesterolemia Drug Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Heterozygous Familial Hypercholesterolemia Drug Sales by Application (2021-2026) & (K Units) Table 35. Global Heterozygous Familial Hypercholesterolemia Drug Sales by Application (2027-2032) & (K Units) Table 36. Global Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Application (2021-2026) Table 37. Global Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Application (2027-2032) Table 38. Global Heterozygous Familial Hypercholesterolemia Drug Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 39. Global Heterozygous Familial Hypercholesterolemia Drug Revenue by Application (2021-2026) & (K Units) Table 40. Global Heterozygous Familial Hypercholesterolemia Drug Revenue by Application (2027-2032) & (K Units) Table 41. Global Heterozygous Familial Hypercholesterolemia Drug Revenue Market Share by Application (2021-2026) Table 42. Global Heterozygous Familial Hypercholesterolemia Drug Revenue Market Share by Application (2027-2032) Table 43. Global Heterozygous Familial Hypercholesterolemia Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Heterozygous Familial Hypercholesterolemia Drug Sales by Region (2021-2026) & (K Units) Table 45. Global Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Region (2021-2026) Table 46. Global Heterozygous Familial Hypercholesterolemia Drug Sales Forecasted by Region (2027-2032) & (K Units) Table 47. Global Heterozygous Familial Hypercholesterolemia Drug Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Heterozygous Familial Hypercholesterolemia Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 49. North America Heterozygous Familial Hypercholesterolemia Drug Sales by Country (2021-2026) & (K Units) Table 50. North America Heterozygous Familial Hypercholesterolemia Drug Sales by Country (2027-2032) & (K Units) Table 51. Europe Heterozygous Familial Hypercholesterolemia Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. Europe Heterozygous Familial Hypercholesterolemia Drug Sales by Country (2021-2026) & (K Units) Table 53. Europe Heterozygous Familial Hypercholesterolemia Drug Sales by Country (2027-2032) & (K Units) Table 54. Asia Pacific Heterozygous Familial Hypercholesterolemia Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Asia Pacific Heterozygous Familial Hypercholesterolemia Drug Sales by Country (2021-2026) & (K Units) Table 56. Asia Pacific Heterozygous Familial Hypercholesterolemia Drug Sales by Country (2027-2032) & (K Units) Table 57. South America, Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. South America, Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Sales by Country (2021-2026) & (K Units) Table 59. South America, Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Sales by Country (2027-2032) & (K Units) Table 60. Global Heterozygous Familial Hypercholesterolemia Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Heterozygous Familial Hypercholesterolemia Drug Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Heterozygous Familial Hypercholesterolemia Drug Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Heterozygous Familial Hypercholesterolemia Drug Revenue Market Share by Region (2021-2026) Table 64. Global Heterozygous Familial Hypercholesterolemia Drug Revenue Market Share by Region (2027-2032) Table 65. Madrigal Pharmaceuticals Inc Company Information Table 66. Madrigal Pharmaceuticals Inc Business Overview Table 67. Madrigal Pharmaceuticals Inc Heterozygous Familial Hypercholesterolemia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Madrigal Pharmaceuticals Inc Heterozygous Familial Hypercholesterolemia Drug Product Portfolio Table 69. Madrigal Pharmaceuticals Inc Recent Development Table 70. Gemphire Therapeutics Inc Company Information Table 71. Gemphire Therapeutics Inc Business Overview Table 72. Gemphire Therapeutics Inc Heterozygous Familial Hypercholesterolemia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Gemphire Therapeutics Inc Heterozygous Familial Hypercholesterolemia Drug Product Portfolio Table 74. Gemphire Therapeutics Inc Recent Development Table 75. Esperion Therapeutics Inc Company Information Table 76. Esperion Therapeutics Inc Business Overview Table 77. Esperion Therapeutics Inc Heterozygous Familial Hypercholesterolemia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Esperion Therapeutics Inc Heterozygous Familial Hypercholesterolemia Drug Product Portfolio Table 79. Esperion Therapeutics Inc Recent Development Table 80. Daewoong Co Ltd Company Information Table 81. Daewoong Co Ltd Business Overview Table 82. Daewoong Co Ltd Heterozygous Familial Hypercholesterolemia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Daewoong Co Ltd Heterozygous Familial Hypercholesterolemia Drug Product Portfolio Table 84. Daewoong Co Ltd Recent Development Table 85. Key Raw Materials Table 86. Raw Materials Key Suppliers Table 87. Heterozygous Familial Hypercholesterolemia Drug Distributors List Table 88. Heterozygous Familial Hypercholesterolemia Drug Customers List Table 89. Research Programs/Design for This Report Table 90. Authors List of This Report Table 91. Secondary Sources Table 92. Primary Sources List of Figures Figure 1. Heterozygous Familial Hypercholesterolemia Drug Product Image Figure 2. Global Heterozygous Familial Hypercholesterolemia Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Heterozygous Familial Hypercholesterolemia Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Heterozygous Familial Hypercholesterolemia Drug Sales (2021-2032) & (K Units) Figure 5. Global Heterozygous Familial Hypercholesterolemia Drug Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Heterozygous Familial Hypercholesterolemia Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Gemcabene Calcium Image Figure 9. ST-103 Image Figure 10. MGL-3196 Image Figure 11. Others Image Figure 12. Global Heterozygous Familial Hypercholesterolemia Drug Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Heterozygous Familial Hypercholesterolemia Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Type (2021-2032) Figure 15. Global Heterozygous Familial Hypercholesterolemia Drug Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global Heterozygous Familial Hypercholesterolemia Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Heterozygous Familial Hypercholesterolemia Drug Revenue Market Share by Type (2021-2032) Figure 18. Clinic Image Figure 19. Hospital Image Figure 20. Others Image Figure 21. Global Heterozygous Familial Hypercholesterolemia Drug Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Heterozygous Familial Hypercholesterolemia Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Application (2021-2032) Figure 24. Global Heterozygous Familial Hypercholesterolemia Drug Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Heterozygous Familial Hypercholesterolemia Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Heterozygous Familial Hypercholesterolemia Drug Revenue Market Share by Application (2021-2032) Figure 27. North America Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 28. North America Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Country (2021-2032) Figure 29. U.S. Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Canada Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Mexico Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Country (2021-2032) Figure 34. Germany Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 35. France Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 36. U.K. Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Italy Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Netherlands Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Country (2021-2032) Figure 41. China Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Japan Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 43. South Korea Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Southeast Asia Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 45. India Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Australia Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Country (2021-2032) Figure 49. Brazil Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South Africa Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Saudi Arabia Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Turkey Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Argentina Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 54. UAE Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Egypt Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Chile Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Global Heterozygous Familial Hypercholesterolemia Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Heterozygous Familial Hypercholesterolemia Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Heterozygous Familial Hypercholesterolemia Drug Revenue (2021-2032) & (US$ Million) Figure 60. North America Heterozygous Familial Hypercholesterolemia Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Heterozygous Familial Hypercholesterolemia Drug Revenue (2021-2032) & (US$ Million) Figure 62. Europe Heterozygous Familial Hypercholesterolemia Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Heterozygous Familial Hypercholesterolemia Drug Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Heterozygous Familial Hypercholesterolemia Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Heterozygous Familial Hypercholesterolemia Drug Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Heterozygous Familial Hypercholesterolemia Drug Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Gemcabene Calcium
  • ST-103
  • MGL-3196
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Madrigal Pharmaceuticals Inc
  • Gemphire Therapeutics Inc
  • Esperion Therapeutics Inc
  • Daewoong Co Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Heterozygous Familial Hypercholesterolemia Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Heterozygous Familial Hypercholesterolemia Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Heterozygous Familial Hypercholesterolemia Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Heterozygous Familial Hypercholesterolemia Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Heterozygous Familial Hypercholesterolemia Drug Market Dynamics
  1. 2.1 Heterozygous Familial Hypercholesterolemia Drug Industry Trends
  2. 2.2 Heterozygous Familial Hypercholesterolemia Drug Industry Drivers
  3. 2.3 Heterozygous Familial Hypercholesterolemia Drug Industry Opportunities and Challenges
  4. 2.4 Heterozygous Familial Hypercholesterolemia Drug Industry Restraints
3 Heterozygous Familial Hypercholesterolemia Drug Market by Manufacturers
  1. 3.1 Global Heterozygous Familial Hypercholesterolemia Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Heterozygous Familial Hypercholesterolemia Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Heterozygous Familial Hypercholesterolemia Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Heterozygous Familial Hypercholesterolemia Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Heterozygous Familial Hypercholesterolemia Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Heterozygous Familial Hypercholesterolemia Drug Manufacturers, Product Type & Application
  7. 3.7 Global Heterozygous Familial Hypercholesterolemia Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Heterozygous Familial Hypercholesterolemia Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Heterozygous Familial Hypercholesterolemia Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Heterozygous Familial Hypercholesterolemia Drug Tier 1, Tier 2, and Tier 3
4 Heterozygous Familial Hypercholesterolemia Drug Market by Type
  1. 4.1 Heterozygous Familial Hypercholesterolemia Drug Type Introduction
  2. 4.1.1 Gemcabene Calcium
  3. 4.1.2 ST-103
  4. 4.1.3 MGL-3196
  5. 4.1.4 Others
  6. 4.2 Global Heterozygous Familial Hypercholesterolemia Drug Sales by Type
  7. 4.2.1 Global Heterozygous Familial Hypercholesterolemia Drug Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Heterozygous Familial Hypercholesterolemia Drug Sales by Type (2021-2032)
  9. 4.2.3 Global Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Type (2021-2032)
  10. 4.3 Global Heterozygous Familial Hypercholesterolemia Drug Revenue by Type
  11. 4.3.1 Global Heterozygous Familial Hypercholesterolemia Drug Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Heterozygous Familial Hypercholesterolemia Drug Revenue by Type (2021-2032)
  13. 4.3.3 Global Heterozygous Familial Hypercholesterolemia Drug Revenue Market Share by Type (2021-2032)
5 Heterozygous Familial Hypercholesterolemia Drug Market by Application
  1. 5.1 Heterozygous Familial Hypercholesterolemia Drug Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global Heterozygous Familial Hypercholesterolemia Drug Sales by Application
  6. 5.2.1 Global Heterozygous Familial Hypercholesterolemia Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Heterozygous Familial Hypercholesterolemia Drug Sales by Application (2021-2032)
  8. 5.2.3 Global Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Application (2021-2032)
  9. 5.3 Global Heterozygous Familial Hypercholesterolemia Drug Revenue by Application
  10. 5.3.1 Global Heterozygous Familial Hypercholesterolemia Drug Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Heterozygous Familial Hypercholesterolemia Drug Revenue by Application (2021-2032)
  12. 5.3.3 Global Heterozygous Familial Hypercholesterolemia Drug Revenue Market Share by Application (2021-2032)
6 Global Heterozygous Familial Hypercholesterolemia Drug Sales by Region
  1. 6.1 Global Heterozygous Familial Hypercholesterolemia Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Heterozygous Familial Hypercholesterolemia Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Heterozygous Familial Hypercholesterolemia Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Heterozygous Familial Hypercholesterolemia Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Heterozygous Familial Hypercholesterolemia Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Heterozygous Familial Hypercholesterolemia Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Heterozygous Familial Hypercholesterolemia Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Heterozygous Familial Hypercholesterolemia Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Heterozygous Familial Hypercholesterolemia Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Heterozygous Familial Hypercholesterolemia Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Heterozygous Familial Hypercholesterolemia Drug Revenue by Region
  1. 7.1 Global Heterozygous Familial Hypercholesterolemia Drug Revenue by Region
  2. 7.1.1 Global Heterozygous Familial Hypercholesterolemia Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Heterozygous Familial Hypercholesterolemia Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Heterozygous Familial Hypercholesterolemia Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Heterozygous Familial Hypercholesterolemia Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Heterozygous Familial Hypercholesterolemia Drug Revenue (2021-2032)
  8. 7.2.2 North America Heterozygous Familial Hypercholesterolemia Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Heterozygous Familial Hypercholesterolemia Drug Revenue (2021-2032)
  11. 7.3.2 Europe Heterozygous Familial Hypercholesterolemia Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Heterozygous Familial Hypercholesterolemia Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Heterozygous Familial Hypercholesterolemia Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Madrigal Pharmaceuticals Inc
  2. 8.1.1 Madrigal Pharmaceuticals Inc Company Information
  3. 8.1.2 Madrigal Pharmaceuticals Inc Business Overview
  4. 8.1.3 Madrigal Pharmaceuticals Inc Heterozygous Familial Hypercholesterolemia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Madrigal Pharmaceuticals Inc Heterozygous Familial Hypercholesterolemia Drug Product Portfolio
  6. 8.1.5 Madrigal Pharmaceuticals Inc Recent Developments
  7. 8.2 Gemphire Therapeutics Inc
  8. 8.2.1 Gemphire Therapeutics Inc Company Information
  9. 8.2.2 Gemphire Therapeutics Inc Business Overview
  10. 8.2.3 Gemphire Therapeutics Inc Heterozygous Familial Hypercholesterolemia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Gemphire Therapeutics Inc Heterozygous Familial Hypercholesterolemia Drug Product Portfolio
  12. 8.2.5 Gemphire Therapeutics Inc Recent Developments
  13. 8.3 Esperion Therapeutics Inc
  14. 8.3.1 Esperion Therapeutics Inc Company Information
  15. 8.3.2 Esperion Therapeutics Inc Business Overview
  16. 8.3.3 Esperion Therapeutics Inc Heterozygous Familial Hypercholesterolemia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Esperion Therapeutics Inc Heterozygous Familial Hypercholesterolemia Drug Product Portfolio
  18. 8.3.5 Esperion Therapeutics Inc Recent Developments
  19. 8.4 Daewoong Co Ltd
  20. 8.4.1 Daewoong Co Ltd Company Information
  21. 8.4.2 Daewoong Co Ltd Business Overview
  22. 8.4.3 Daewoong Co Ltd Heterozygous Familial Hypercholesterolemia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Daewoong Co Ltd Heterozygous Familial Hypercholesterolemia Drug Product Portfolio
  24. 8.4.5 Daewoong Co Ltd Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Heterozygous Familial Hypercholesterolemia Drug Value Chain Analysis
  2. 9.1.1 Heterozygous Familial Hypercholesterolemia Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Heterozygous Familial Hypercholesterolemia Drug Production Mode & Process
  6. 9.2 Heterozygous Familial Hypercholesterolemia Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Heterozygous Familial Hypercholesterolemia Drug Distributors
  9. 9.2.3 Heterozygous Familial Hypercholesterolemia Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst